Combining elements of four hormones into a single drug, researchers hope to address not only obesity, but associated conditions like type 2 diabetes, cancer, and cardiovascular disease
A tetra-agonist peptide (foreground helix) does the work of four separate hormones by binding to four different receptors (shown on the cell in red/blue, violet, blue, and green). “What drives us is the idea that we can design a single drug to treat obesity and simultaneously mitigate the risk of developing a long list of health problems plaguing society,” says Krishna Kumar. Image: Hassan @ScienceBrush
Latest Stories
Research at Tufts
The university’s faculty and students are driving thinking and research forward to solve our most pressing challenges—in our communities and around the world.
